Vaccine (DNA plasmid) · Immune activation, directed at Lassa virus nucleoprotein · developed by INOVIO PHARMACEUTICALS
INO-4500 is a plasmid DNA vaccine administered intradermally for Lassa fever. It is designed to elicit immune responses against Lassa virus antigens.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04093076 | Phase 1 | Lassa Fever | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lassa Fever
Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →